FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to the diagnosis of a simple form of schizophrenia. The use of serine/threonine protein kinase (DCLK1) proteins at concentrations above 22.3 ng/ml and receptor serine/threonine protein kinase 1 (RIPK1) at concentrations above 51.5 ng/ml in serum as biomarkers of simple schizophrenia.
EFFECT: above invention makes it possible to use the identification of biomarkers for the differential diagnosis of a simple form of schizophrenia.
1 cl, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LABORATORY DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR ENDOGENOUS PSYCHOSIS | 2013 |
|
RU2522236C1 |
| LABORATORY METHOD OF DIAGNOSING BIPOLAR AFFECTIVE DISORDER | 2013 |
|
RU2558056C2 |
| METHOD FOR PREDICTION OF COMORBID COURSE OF AFFECTIVE DISORDERS AND ALCOHOLISM BASED ON DETERMINATION OF BLOOD SERUM PROTEINS | 2021 |
|
RU2767699C1 |
| LABORATORY DIAGNOSTIC TECHNIQUE FOR SCHIZOTYPAL DISORDER | 2014 |
|
RU2569741C1 |
| METHOD FOR RAPID DIAGNOSIS OF THE FORM OF DISORDER OF SCHIZOPHRENIC SPECTRUM | 2018 |
|
RU2653682C1 |
| METHOD OF ASSESSING THE RISK OF AGGRESSIVE BEHAVIOR IN PERSONS WITH SEVERE MENTAL DISORDERS | 2023 |
|
RU2804673C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2775440C1 |
| DIAGNOSTIC TECHNIQUE FOR METABOLIC SYNDROME IN SCHIZOPHRENIC PATIENTS RECEIVING NEUROLEPTIC THERAPY | 2019 |
|
RU2717367C1 |
| LABORATORY METHOD FOR DIAGNOSIS OF LEADING NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA | 2015 |
|
RU2578957C1 |
| METHOD FOR PREDICTION OF RISK OF PARANOID SCHIZOPHRENIA | 2012 |
|
RU2506595C2 |
